Live Breaking News & Updates on Io101

Stay updated with breaking news from Io101. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Biophytis Announces the Signature of a Master Service Agreement With Intsel Chimos, a Pharmaceutical Company That Will Operate Sarconeos (BIO101) in France for the Treatment of Severe Forms of COVID-19

Biophytis and Intsel Chimos signed a master service agreement under which Intsel Chimos will be the operating pharmaceutical company/exploitant, partner and ....

United Kingdom , United States , France General , Intsel Chimos , Agathe Boggio , Antoine Denry , Corinne Truffault , National Agency For The Safety Of Medicines , Exchange Commission , Company Or Biophytis , French National Authority For Health , Uncertainties Facing The Company , Health Products , Haute Autorit , French National Authority , Pharmaceutical Operator , National Agency , Latin America , Euronext Growth , American Depositary Shares , Nasdaq Capital Market , Uncertainties Facing , Covid 19 ,

Biophytis Received Approval from ANVISA (Brazil) to Give Access to Sarconeos (BIO101) to Hospitalized COVID-19 Patients through an Expanded Access Program

ANVISA (Brazilian Health Authority) approved Biophytis' Expanded Access Program (EAP) for hospitalized patients with severe COVID-19 and mechanically ventilated in Intensive Care UnitSarconeos (BIO101) ....

Sao Paulo , United States , France General , United Kingdom , Agathe Boggio , Suzana Lobo , Evelyne Nguyen , Antoine Denry , Ludhmila Hajjar , Hospital De , Exchange Commission , Anvisa Brazilian Health Authority , Sorbonne University , Biophyti Expanded Access Program , Care Division , Access Program , Brazilian Health Authority , Intensive Care , Intensive Care Units , Latin America , Euronext Growth Paris , Expanded Access Program , Intensive Care Unit , Principal Investigator , Intensive Care Division , Duchenne Muscular Dystrophy ,

Biophytis to Meet with FDA to Advance Sarconeos (BIO101) Development in Sarcopenia from Phase 2 to Phase 3

Following Phase2b/SARA-INT clinically meaningful results, Biophytis is starting first regulatory activities to advance from Phase 2 to Phase 3 developmentA Type B/End-of-Phase 2 meeting is planned with ....

United Kingdom , United States , France General , Agathe Boggio , Evelyne Nguyen , Antoine Denry , Exchange Commission , Drug Administration On , Drug Administration , European Medicine Agency , Following Phase , Euronext Growth Paris , Meter Walk Test , Serious Adverse Events , Latin America , Duchenne Muscular Dystrophy , Euronext Growth , American Depositary Shares , Year Report ,